311 related articles for article (PubMed ID: 26271358)
1. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.
Safroneeva E; Vavricka SR; Fournier N; Pittet V; Peyrin-Biroulet L; Straumann A; Rogler G; Schoepfer AM;
Aliment Pharmacol Ther; 2015 Oct; 42(8):977-89. PubMed ID: 26271358
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
3. The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn's Disease.
Yu CS; Jung SW; Lee JL; Lim SB; Park IJ; Yoon YS; Kim CW; Yang SK; Ye BD; Park SH; Han M; Kim JC
Inflamm Bowel Dis; 2019 Aug; 25(9):1559-1568. PubMed ID: 30753560
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn's disease of inflammatory type.
Nagata Y; Esaki M; Moriyama T; Hirano A; Umeno J; Maehata Y; Torisu T; Matsumoto T; Kitazono T
J Gastroenterol; 2019 Apr; 54(4):330-338. PubMed ID: 30244398
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease.
Osterman MT; Haynes K; Delzell E; Zhang J; Bewtra M; Brensinger CM; Chen L; Xie F; Curtis JR; Lewis JD
Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1293-1301.e5; quiz e70, e72. PubMed ID: 25724699
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Bowel Surgery and Associated Risk Factors in Pediatric-Onset Crohn's Disease.
Rinawi F; Assa A; Hartman C; Mozer Glassberg Y; Friedler VN; Rosenbach Y; Silbermintz A; Zevit N; Shamir R
Inflamm Bowel Dis; 2016 Dec; 22(12):2917-2923. PubMed ID: 27755214
[TBL] [Abstract][Full Text] [Related]
7. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
8. Crohn's disease prognosis and early immunomodulator therapy: Results from the CONNECT study.
Kim B; Cheon JH; Moon HJ; Park YR; Ye BD; Yang SK; Seo GS; Jang BI; Kim YS; Kim JS; Han DS; Kim YH; Kim WH
J Gastroenterol Hepatol; 2016 Jan; 31(1):126-32. PubMed ID: 26406334
[TBL] [Abstract][Full Text] [Related]
9. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort.
Nuti F; Civitelli F; Bloise S; Oliva S; Aloi M; Latorre G; Viola F; Cucchiara S
J Crohns Colitis; 2016 Jan; 10(1):5-12. PubMed ID: 26188350
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
[TBL] [Abstract][Full Text] [Related]
11. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors.
Oh EH; Oh K; Han M; Seo H; Chang K; Lee SH; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
PLoS One; 2017; 12(5):e0177479. PubMed ID: 28542298
[TBL] [Abstract][Full Text] [Related]
12. Intravenous Versus Subcutaneous Anti-TNF-Alpha Agents for Crohn's Disease: A Comparison of Effectiveness and Safety.
Liu J; Sylwestrzak G; Ruggieri AP; DeVries A
J Manag Care Spec Pharm; 2015 Jul; 21(7):559-66. PubMed ID: 26108380
[TBL] [Abstract][Full Text] [Related]
13. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome.
Fiorino G; Morin M; Bonovas S; Bonifacio C; Spinelli A; Germain A; Laurent V; Zallot C; Peyrin-Biroulet L; Danese S
J Crohns Colitis; 2017 Mar; 11(3):274-280. PubMed ID: 27799269
[TBL] [Abstract][Full Text] [Related]
16. Tumor Necrosis Factor Inhibitors May Have Limited Efficacy for Complex Perianal Fistulas Without Luminal Crohn's Disease.
McCurdy JD; Parlow S; Dawkins Y; Samji K; Rhee GG; Oliveira L; Macdonald B; Sabri E; Murthy S
Dig Dis Sci; 2020 Jun; 65(6):1784-1789. PubMed ID: 31642006
[TBL] [Abstract][Full Text] [Related]
17. Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease.
Pittet V; Rogler G; Michetti P; Fournier N; Vader JP; Schoepfer A; Mottet C; Burnand B; Froehlich F;
Digestion; 2013; 87(3):212-21. PubMed ID: 23711401
[TBL] [Abstract][Full Text] [Related]
18. Systematic Analysis of the Impact of Diagnostic Delay on Bowel Damage in Paediatric Versus Adult Onset Crohn's Disease.
Schoepfer A; Santos J; Fournier N; Schibli S; Spalinger J; Vavricka S; Safroneeva E; Aslan N; Rogler G; Braegger C; Nydegger A
J Crohns Colitis; 2019 Sep; 13(10):1334-1342. PubMed ID: 31002741
[TBL] [Abstract][Full Text] [Related]
19. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
20. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
Protic M; Schoepfer A; Yawalkar N; Vavricka S; Seibold F
Scand J Gastroenterol; 2016 Dec; 51(12):1482-1488. PubMed ID: 27534974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
